NCT02868242View on ClinicalTrials.gov

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 28, 2016

Primary Completion Date

November 12, 2018

Study Completion Date

February 3, 2019

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

LDV/SOF

Tablet(s) administered orally once daily

Trial Locations (1)

Unknown

National Cancer Institute, Cairo University, Cairo

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY